IRVINE, Calif.--(BUSINESS WIRE)--Endologix, Inc. (NASDAQ: ELGX - News), the developer and manufacturer of the Powerlink® System for the minimally invasive treatment of abdominal aortic aneurysms (AAA), today announced that data from its prospective, multicenter clinical trial of the Powerlink Suprarenal Proximal Extension System will be presented for the first time on March 19, 2009 at the Society for Clinical Vascular Surgery’s (SCVS) 37th Annual Symposium being held in Ft. Lauderdale, Fla. Endologix is currently marketing the Powerlink Suprarenal Extensions following receipt of U.S. Food and Drug Administration approval in October 2008.
Stuart A. Harlin, M.D., FACS, of Sacred Heart Medical Center in Pensacola, Fla., who was a principal investigator in this trial, will discuss the data and results in a presentation entitled, “EVAR Using an Anatomical Fixation Technique and Concomitant Suprarenal Orientation: Results of a Prospective, Multicenter Trial.” Endologix plans to announce these clinical data in a press release to be issued following the presentation.
The Powerlink Suprarenal Proximal Extension is designed with an open cell stent extending above the graft material to allow the physician to position the device at the proximal landing zone without obstructing renal arteries. The device is available in multiple diameters and lengths and can treat patients with aortic necks up to 32 millimeters in diameter.
“We are pleased with the continued exceptional clinical results from the Powerlink device and look forward to sharing this information with the vascular community at the SCVS symposium,” said John McDermott, Endologix President and CEO. “The Powerlink System includes the only available unibody stent graft for the treatment of AAA that facilitates anatomical fixation. The availability of proximal extensions in suprarenal or infrarenal configuration gives physicians a clinical choice for the treatment of a wide range of patient anatomies, including large diameter aortic necks.”
About Endologix
Endologix, Inc. develops and manufactures innovative therapies for aortic disorders. The company’s IntuiTrak System is an endovascular stent graft for treating abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Additional information can be found on Endologix’s Web site at www.endologix.com.
Except for historical information contained herein, this news release contains forward-looking statements, the accuracy of which are necessarily subject to risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond the control of Endologix. The Company undertakes no obligation to update its forward-looking statements. Please refer to the Company’s Annual Report on Form 10-K for the year ended December 31, 2008, and the Company’s other filings with the Securities and Exchange Commission, for more detailed information regarding these risks and other factors that may cause actual results to differ materially from those expressed or implied.
Contact:
Company Contact: Endologix, Inc. John McDermott, President and CEO 949-595-7200 www.endologix.com or Investor Contacts: Lippert/Heilshorn & Associates, Inc. Bruce Voss, bvoss@lhai.com Jody Cain, jcain@lhai.com 310-691-7100 www.lhai.com
